Vanguard Global Advisers’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
Other funds holding VRDN
KCM
Vanguard Global Advisers's VRDN Position: Q3 2026 in Review
Vanguard Global Advisers increased its Viridian Therapeutics (VRDN) stake by 7.9% in Q3 2026, buying an estimated $69K and bringing the position to 43,981 shares worth $906K. The position accounts for ﹤0.01% of the portfolio, ranked #1772.
Vanguard Global Advisers first reported a position in VRDN in Q1 2026 and has held it in 3 quarters since. 235 funds tracked by Wall St. Rank hold VRDN as of Q3 2026.
- Vanguard Global Advisers held 43,981 shares of Viridian Therapeutics worth $906K as of Q3 2026.
- Vanguard Global Advisers bought 3,231 Viridian Therapeutics shares in Q3 2026, an estimated $69K.
- Viridian Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #1772 holding.
- Vanguard Global Advisers first reported a position in Viridian Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 235 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.